LEXINGTON -- Six-month-old Predictive Biosciences, which is using technology licensed from Children’s Hospital Boston to create noninvasive cancer diagnosis products, received $10 million in first-round funding from co-lead investors Highland Capital Partners in Lexington and IDG Ventures Boston.
